Amgen, Inc.

NASDAQ: AMGN
$248.95
+$2.07 (+0.8%)
Closing price April 9, 2021
With the first quarter soon coming to an end, now is the time to move from momentum to strong growth stocks. Goldman Sachs feels these four could offer extra strength in a pricey stock market.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.
Tuesday's top analyst upgrades and downgrades included Amgen, Amphenol, Continental Resources, EOG Resources, FedEx, IMAX and Splunk.
One popular investment strategy, known as the Dogs of the Dow, has performed better than last year. What's ahead for the dogs in 2021?
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amazon.com, Amgen, Biogen, Hasbro, Kinder Morgan, SAP, Spotify and Twitter.
Monday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, Asana, Baidu, First Solar, Mattel, Mirati Therapeutics, Palantir Technologies, Pinterest, SAP and Zscaler.
Roughly a third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.